Document:

Exhibit 10.8

 

Global Consumer Acquisition Corp.

 

[__], 2021

 

ARC Group Limited

 

 

Re: Administrative
Support Agreement

 

Ladies and Gentlemen:

 

This letter agreement
by and between Global Consumer Acquisition Corp. (the “Company”) and ARC Group Limited (“ARC Group”), dated
as of the date hereof, will confirm our agreement that, commencing on the date the securities of the Company are first listed on
The Nasdaq Capital Market (the “Listing Date”), pursuant to a Registration Statement on Form S-1 and related prospectus
filed with the U.S. Securities and Exchange Commission (the “Registration Statement”) and continuing until the earlier
of the consummation by the Company of an initial business combination or the Company’s liquidation (in each case as described
in the Registration Statement) (such earlier date hereinafter referred to as the “Termination Date”):

 

(i) ARC Group
shall make available, or cause to be made available, to the Company at ______________ (or any successor location of ARC Group),
certain office space, utilities and secretarial and administrative support as may be reasonably required by the Company. In exchange
therefor, the Company shall pay ARC Group the sum of $10,000 per month on the Listing Date and continuing monthly thereafter until
the Termination Date; and

 

(ii) ARC Group
hereby irrevocably waives any and all right, title, interest, causes of action and claims of any kind as a result of, or arising
out of, this letter agreement in or to, and any and all right to seek payment of any amounts due to it (each, a “Claim”)
out of, the trust account established for the benefit of the public stockholders of the Company and into which substantially all
of the proceeds of the Company’s initial public offering will be deposited (the “Trust Account”) as a result
of, or arising out of, this letter agreement, and hereby irrevocably waives any Claim it may have in the future, which Claim would
reduce, encumber or otherwise adversely affect the Trust Account or any monies or other assets in the Trust Account, and further
agrees not to seek recourse, reimbursement, payment or satisfaction of any Claim against the Trust Account or any monies or other
assets in the Trust Account for any reason whatsoever.

 

This letter agreement
constitutes the entire agreement and understanding of the parties hereto in respect of its subject matter and supersedes all prior
understandings, agreements, or representations by or among the parties hereto, written or oral, to the extent they relate in any
way to the subject matter hereof or the transactions contemplated hereby.

 

This letter agreement
may not be amended, modified or waived as to any particular provision, except by a written instrument executed by the parties hereto.

 

No party hereto may
assign either this letter agreement or any of its rights, interests, or obligations hereunder without the prior written approval
of the other party. Any purported assignment in violation of this paragraph shall be void and ineffectual and shall not operate
to transfer or assign any interest or title to the purported assignee.

 

This letter agreement
constitutes the entire relationship of the parties hereto, and any litigation between the parties (whether grounded in contract,
tort, statute, law or equity) shall be governed by, construed in accordance with, and interpreted pursuant to the laws of the State
of New York, without giving effect to its choice of law principles.

 

 

 

[Signature Page Follows]

 

     

     

    

 

	 	Very truly yours,
	 	 
	 	GLOBAL CONSUMER ACQUISITION CORP.
	 	 	 
	 	By:	 
	 	 	Name:	 Rohan Ajila
	 	 	Title:	Chief Executive Officer

 

 

AGREED TO AND ACCEPTED BY:

 

ARC GROUP LIMITED

 

	By:	 	 
	 	Name: Abraham Cinta	 
	 	Title:   Chief Executive Officer	 

 

 

[Signature Page to Administrative
Support Agreement]Execution Version
[***] = CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED AND HAS BEEN MARKED WITH “[***]” TO INDICATE WHERE OMISSIONS HAVE BEEN MADE.

Exhibit 10.29
AMENDMENT No. 1
to the Research and License Agreement
between Xencor, Inc. and Amgen Inc.
This Amendment No. 1 (“Amendment”) is entered into as of November 22, 2019 (“Amendment No. 1 Effective Date”) by and between Xencor, Inc., a corporation organized under the laws of the State of Delaware (“Xencor”), having an address of 111 West Lemon Avenue, Monrovia, California 91016 and Amgen Inc., a Delaware corporation having its principal place of business at One Amgen Center Drive, Thousand Oaks, California 91320- 1799, USA (“Amgen”). Xencor and Amgen are each referred to individually as a “Party” and together as the “Parties”.
WHEREAS, Xencor and Amgen are parties to a Research and License Agreement dated as of September 15, 2015 (the “Agreement”);
WHEREAS, the Parties mutually desire to amend, modify and restate certain terms and conditions of the Agreement regarding the payment of a certain milestone payment;
NOW THEREFORE, in consideration of the mutual promises contained herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, and intending to be legally bound, the Parties hereto agree as follows:
1.DEFINITIONS
Unless otherwise defined herein, capitalized words in this Amendment shall have the meaning attributed to them in the Agreement.
The following defined term is added to the Agreement:
[***]
2.AMENDMENT
The Parties agree that, as of the Amendment No. 1 Effective Date, the Agreement is amended as set forth in this Section 2.
Section 7.2 (a)(ii) of the Agreement is deleted in its entirety and replaced with the following:
“(ii) with respect to the first occurrence of the corresponding Milestone for a Product containing or comprising a Discovery Program Compound:
​

​

​

	​

	​

	Milestone
	Milestone Payment

	1. Development Milestones
	​

	(a) [***]
	$      [***]

	(b) [***]
	$      [***]

	(c) [***]
	$      [***]

	(d) [***]
	$      [***]

	(e) [***]
	$      [***]

	(f) [***]
	$      [***]

	(g) [***]
	$      [***]

	2. Sales Milestones
	​

	(a) [***]
	$      [***]

	(b) [***]
	$      [***]

	3. Total Milestone Payments for each Discovery Program
	$      260,500,000

3.INTEGRATION
Except for the section of the Agreement specifically amended hereunder, all terms and conditions of the Agreement remain and shall remain in full force and effect. This Amendment shall hereafter be incorporated into and deemed part of the Agreement and any future reference to the Agreement shall include the terms and conditions of this Amendment.
4.APPLICABLE LAW & JURISDICTION
This Amendment shall be governed by, and construed in accordance with, the laws which govern the Agreement, and the Parties submit to the jurisdiction and dispute resolution provisions as set forth in the Agreement.
5.COUNTERPARTS
This Amendment may be executed in counterparts with the same effect as if both Parties had signed the same document. All such counterparts shall be deemed an original, shall be construed together and shall constitute one and the same instrument. Signature pages of this Amendment may be exchanged by facsimile or other electronic means without affecting the validity thereof.
[Remainder of Page Intentionally Left Blank - Signature Page to Follow]
​

	​

	​

	Amgen Contract No:
	Page 2 of 3

[***] = CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED AND HAS BEEN MARKED WITH “[***]” TO INDICATE WHERE OMISSIONS HAVE BEEN MADE.

​

Execution Version
IN WITNESS WH ERE OF, the Par tie s intend i ng to be bound have caused this Amendment to be executed by their duly authorized representatives.

	​

	​

	Amgen Contract No:
	Page 3 of 3

[***] = CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED AND HAS BEEN MARKED WITH “[***]” TO INDICATE WHERE OMISSIONS HAVE BEEN MADE.[***] = CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED, AND HAS BEEN MARKED WITH “[***]” TO INDICATE WHERE OMISSIONS HAVE BEEN MADE.
​

Exhibit 10.30
Amendment to the Cross-License Agreement
By and Between
MedImmune, LLC and Xencor, Inc.
This amendment ("Amendment") to the license agreement effected December 19, 2012 (the "Agreement") by and between MedImmune, LLC, a limited liability company organized under the laws of Delaware, having a principal place of business at One MedImmune Way, Gaithersburg MD 20878 (“MedImmune”) and Xencor, Inc., a Delaware corporation with an office at 111 W. Lemon Ave., Monrovia, CA 91016 ("Xencor"), is effective as of January 2, 2020.  Capitalized terms not otherwise defined herein shall have the meaning ascribed in the Agreement.
Whereas, MedImmune and Xencor desire to amend the Agreement in order to make the process of milestone payments more efficient; and
Whereas, MedImmune began doing business as AstraZeneca in February of 2019.
Now Therefore, in consideration of the mutual promises and covenants herein contained, Xencor and MedImmune hereby agree to the following terms:

	1.	Section 2.5 (b) shall be deleted and replaced with the following: 	

“providing reports pursuant to Section 5.4 of the [***] License to 
 ​
[***]

	2.	The first paragraph of Section 6.1 shall be deleted and replaced with the following:	

“Xencor shall make payments to [***] pursuant to Section 5 of the [***] License and calculated according to the terms of the [***] License as applied to all activities, achievements and sales pursuant to Xencor’s sublicense hereunder of [***]’s interest in those MedImmune Patents co-owned by MedImmune. Xencor shall make payments pursuant to Section 5.1 (c) of the [***] License within thirty (30) days of each milestone event and payments pursuant to Section 5.1 (d) of the [***] License shall be due and payable by March 1 of each year during the term of the [***] License.” 

	3.	Section 6.2 shall be deleted and replaced with the following sentence: 	

“All payment to [***] shall be made via the following methods unless advised differently by [***]: 

[***]

	4.	Except as expressly and unambiguously stated herein, all other terms and conditions of the Agreement, as amended, shall remain in full force and effect.	

​
[Signature Page Follows]
​

[***] = CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED, AND HAS BEEN MARKED WITH “[***]” TO INDICATE WHERE OMISSIONS HAVE BEEN MADE.
2

​

​
​
In Witness Whereof, the parties have caused this Amendment to be executed by their duly authorized representatives.
	Xencor, Inc.
	MedImmune, LLC

​
By: ​ ​/s/ Bassil Dahiyat​ ​​ ​By: ​ ​/s/ Gail Wasserman​ ​​ ​
Name: ​ ​Bassil Dahiyat​ ​​ ​​ ​Name: ​ ​ Gail Wasserman​ ​​ ​
Title: ​ ​President & CEO​ ​​ ​Title: ​ ​​ ​​ ​​ ​​ ​
Date: ​ ​03 January 2020​ ​​ ​Date: ​ ​13 January 2020​ ​​ ​
​
​
​
Acknowledged by:
[***]
By: ​ ​[***]​ ​​ ​​ ​​ ​
Name: ​ ​[***]​ ​​ ​​ ​​ ​
Title: ​ ​[***]​ ​​ ​​ ​​ ​
Date: ​ ​​ ​04 January 2020​ ​

[***] = CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED, AND HAS BEEN MARKED WITH “[***]” TO INDICATE WHERE OMISSIONS HAVE BEEN MADE.
3

​

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00321-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00321-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00321-of-00352.parquet"}]]